Advancement in lipid-based nanocomposites for theranostic applications in lung carcinoma treatment

Q2 Pharmacology, Toxicology and Pharmaceutics OpenNano Pub Date : 2024-01-01 DOI:10.1016/j.onano.2023.100199
Viola Colaco, Amrita Arup Roy, Gaurisha Alias Resha Ramnath Naik, Arijit Mondal, Srinivas Mutalik, Namdev Dhas
{"title":"Advancement in lipid-based nanocomposites for theranostic applications in lung carcinoma treatment","authors":"Viola Colaco,&nbsp;Amrita Arup Roy,&nbsp;Gaurisha Alias Resha Ramnath Naik,&nbsp;Arijit Mondal,&nbsp;Srinivas Mutalik,&nbsp;Namdev Dhas","doi":"10.1016/j.onano.2023.100199","DOIUrl":null,"url":null,"abstract":"<div><p>On a global scale, lung cancer remains a common malignancy and is largest cause of many deaths related to cancer. Despite the significant advancements in lung cancer diagnostic and therapeutic approaches, many individuals exhibit resistant responses to proven therapies. This focuses on the critical need for novel therapeutic methods to be developed and innovated. Recently, nanotechnology has gained a lot of importance for treating malignancy as it helps improve drug delivery, specificity, reduced dose, and efficient elimination. Lipid nanoparticles (LNPs) are nanocarriers with low particle size, which can be modified for specific delivery. The current review focuses on the significance and application of lipid-based theranostic nanoparticles for cancer therapy, components, method of preparation and factors affecting lipid nanoparticle preparation, along with the clinical trials and patents of LNPs. Therapeutic applications in lung cancer therapy include Chemotherapy, photodynamic therapy, immunotherapy, gene therapy, photothermal therapy, and sonodynamic therapy. Diagnostic applications like SPECT, CT, MRI, PET, Optical fluorescence imaging and NIR. As LNPs are being used more frequently in lung cancer therapy, the ongoing research helps in offering solutions to overcome the issues by conventional treatments. Due to their adaptability to customized medical procedures and the use of numerous components, they hold the potential for treating lung cancer. In conclusion, LNPs offer a viable strategy for treating lung cancer by boosting bioavailability, promoting medication delivery, and removing obstacles. For individualised medicine, they can encapsulate a range of therapeutic, such as immunomodulatory medicines, siRNA, and chemotherapeutic medications. Additional study and clinical validation are required to address scalability, long-term safety, and optimised manufacturing techniques for effective application in lung cancer therapy.</p></div>","PeriodicalId":37785,"journal":{"name":"OpenNano","volume":"15 ","pages":"Article 100199"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352952023000786/pdfft?md5=fde8e6706154857844db7b074cd405c1&pid=1-s2.0-S2352952023000786-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OpenNano","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352952023000786","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

On a global scale, lung cancer remains a common malignancy and is largest cause of many deaths related to cancer. Despite the significant advancements in lung cancer diagnostic and therapeutic approaches, many individuals exhibit resistant responses to proven therapies. This focuses on the critical need for novel therapeutic methods to be developed and innovated. Recently, nanotechnology has gained a lot of importance for treating malignancy as it helps improve drug delivery, specificity, reduced dose, and efficient elimination. Lipid nanoparticles (LNPs) are nanocarriers with low particle size, which can be modified for specific delivery. The current review focuses on the significance and application of lipid-based theranostic nanoparticles for cancer therapy, components, method of preparation and factors affecting lipid nanoparticle preparation, along with the clinical trials and patents of LNPs. Therapeutic applications in lung cancer therapy include Chemotherapy, photodynamic therapy, immunotherapy, gene therapy, photothermal therapy, and sonodynamic therapy. Diagnostic applications like SPECT, CT, MRI, PET, Optical fluorescence imaging and NIR. As LNPs are being used more frequently in lung cancer therapy, the ongoing research helps in offering solutions to overcome the issues by conventional treatments. Due to their adaptability to customized medical procedures and the use of numerous components, they hold the potential for treating lung cancer. In conclusion, LNPs offer a viable strategy for treating lung cancer by boosting bioavailability, promoting medication delivery, and removing obstacles. For individualised medicine, they can encapsulate a range of therapeutic, such as immunomodulatory medicines, siRNA, and chemotherapeutic medications. Additional study and clinical validation are required to address scalability, long-term safety, and optimised manufacturing techniques for effective application in lung cancer therapy.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于脂质的纳米复合材料在肺癌治疗中的治疗应用进展
在全球范围内,肺癌仍然是一种常见的恶性肿瘤,也是导致许多人死于癌症的最大原因。尽管肺癌诊断和治疗方法取得了重大进展,但许多患者对已证实的疗法表现出抗药性。这就迫切需要开发和创新新型治疗方法。最近,纳米技术在治疗恶性肿瘤方面获得了极大的重视,因为它有助于改善药物输送、特异性、减少剂量和有效清除。脂质纳米颗粒(LNPs)是一种粒径较小的纳米载体,可进行改性以实现特异性给药。本综述重点介绍了脂质治疗纳米粒子在癌症治疗中的意义和应用、成分、制备方法和影响脂质纳米粒子制备的因素,以及 LNPs 的临床试验和专利情况。肺癌治疗应用包括化疗、光动力疗法、免疫疗法、基因疗法、光热疗法和声动力疗法。诊断应用包括 SPECT、CT、MRI、PET、光学荧光成像和近红外。由于 LNPs 在肺癌治疗中的应用越来越广泛,正在进行的研究有助于为克服传统治疗方法的问题提供解决方案。由于 LNPs 可适应定制的医疗程序,并可使用多种成分,因此具有治疗肺癌的潜力。总之,LNPs 通过提高生物利用度、促进药物输送和消除障碍,为治疗肺癌提供了一种可行的策略。对于个体化治疗,它们可以封装一系列治疗药物,如免疫调节药物、siRNA 和化疗药物。要在肺癌治疗中有效应用,还需要进行更多的研究和临床验证,以解决可扩展性、长期安全性和优化生产技术等问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
OpenNano
OpenNano Medicine-Pharmacology (medical)
CiteScore
4.10
自引率
0.00%
发文量
63
审稿时长
50 days
期刊介绍: OpenNano is an internationally peer-reviewed and open access journal publishing high-quality review articles and original research papers on the burgeoning area of nanopharmaceutics and nanosized delivery systems for drugs, genes, and imaging agents. The Journal publishes basic, translational and clinical research as well as methodological papers and aims to bring together chemists, biochemists, cell biologists, material scientists, pharmaceutical scientists, pharmacologists, clinicians and all others working in this exciting and challenging area.
期刊最新文献
Fundamentals behind the success of nanotechnology in cancer treatment and diagnosis Cellular viability in an in vitro model of human ventricular cardiomyocytes (RL-14) exposed to gold nanoparticles biosynthesized using silk fibroin from silk fibrous waste Fabrication of pyrroloquinoline quinone-loaded small unilamellar vesicles through various downsizing techniques for biomedical applications A recent advances in antimicrobial activity of green synthesized selenium nanoparticle The effect of coating chitosan from cuttlefish bone (Sepia Sp.) on the surface of orthodontic mini-screw
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1